For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Akebia Therapeutics Inc (NASDAQ: AKBA) closed the day trading at $3.01 down -20.48% from the previous closing price of $3.79. In other words, the price has decreased by -$20.48 from its previous closing price. On the day, 14.76 million shares were traded. AKBA stock price reached its highest trading level at $3.28 during the session, while it also had its lowest trading level at $2.9201.
Ratios:
For a better understanding of AKBA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.02 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 8.39 whereas as Long-Term Debt/Eq ratio is at 7.41.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7. On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 994076544 and an Enterprise Value of 1076298624. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.28 while its Price-to-Book (P/B) ratio in mrq is 32.04. Its current Enterprise Value per Revenue stands at 5.821 whereas that against EBITDA is 105.499.
Stock Price History:
The Beta on a monthly basis for AKBA is 1.03, which has changed by 1.7117116 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.07. The 50-Day Moving Average of the stock is -17.69%, while the 200-Day Moving Average is calculated to be 23.37%.
Shares Statistics:
Over the past 3-months, AKBA traded about 4.79M shares per day on average, while over the past 10 days, AKBA traded about 4534460 shares per day. A total of 261.64M shares are outstanding, with a floating share count of 251.62M. Insiders hold about 4.19% of the company’s shares, while institutions hold 35.60% stake in the company. Shares short for AKBA as of 1752537600 were 25373233 with a Short Ratio of 5.30, compared to 1749772800 on 18498837. Therefore, it implies a Short% of Shares Outstanding of 25373233 and a Short% of Float of 9.7600006.
Earnings Estimates
The market rating for Akebia Therapeutics Inc (AKBA) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.02 and -$0.02 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is $0.11, with 1.0 analysts recommending between $0.11 and $0.11.
Revenue Estimates
5 analysts predict $47.89M in revenue for the current quarter. It ranges from a high estimate of $55.15M to a low estimate of $44M. As of the current estimate, Akebia Therapeutics Inc’s year-ago sales were $37.43MFor the next quarter, 5 analysts are estimating revenue of $50.29M. There is a high estimate of $58.36M for the next quarter, whereas the lowest estimate is $43.3M.
A total of 5 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $233.32M, while the lowest revenue estimate was $192.8M, resulting in an average revenue estimate of $208.7M. In the same quarter a year ago, actual revenue was $160.18MBased on 5 analysts’ estimates, the company’s revenue will be $289.25M in the next fiscal year. The high estimate is $396.3M and the low estimate is $216.9M.
